Exenatide vs Eloralintide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Byetta, Bydureon
The first GLP-1 receptor agonist approved for diabetes. Derived from Gila monster saliva. Available in twice-daily and weekly formulations.
Also: GSBR-1290, Structure GSBR-1290
A next-generation oral GLP-1 receptor agonist developed by Structure Therapeutics (now Ventyx Biosciences). Shows comparable weight loss to injectable GLP-1s with potentially fewer gastrointestinal side effects and a longer half-life, allowing flexible dosing.
Key Comparison Insights
- Exenatide is FDA approved, while Eloralintide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Exenatide has stronger research evidence (FDA Approved) compared to Eloralintide (Phase 2 Clinical Trial).
Detailed Comparison
| Attribute | Exenatide | Eloralintide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Exenatide is a synthetic version of exendin-4 from Gila monster venom. It shares 53% homology with human GLP-1 and resists DPP-4 degradation. Activates GLP-1 receptors to improve glucose control and reduce appetite. | Eloralintide is a small-molecule, non-peptide GLP-1 receptor agonist that mimics the action of GLP-1. Unlike traditional peptide-based GLP-1 agonists, it is orally bioavailable without requiring absorption enhancers. It activates GLP-1 receptors to suppress appetite, slow gastric emptying, and enhance glucose-dependent insulin secretion. |
| Common Dosing | 5-10 mcg twice daily or 2 mg weekly Twice daily (IR) or once weekly (ER) | 120-240mg once daily (oral) Once daily |
| Administration | Subcutaneous injection | Oral tablet |
| Typical Duration | Long-term / chronic use | 36 weeks in Phase 2 trials |
| Best Time to Take | Before bed or morning (fasted) | - |
Possible Side Effects May vary by individual |
|
|
| Research Summary | First-in-class GLP-1 agonist with extensive clinical experience since 2005. Studies show 2-4% weight loss and A1C reductions of 0.5-1%. Weekly formulation (Bydureon) provides more consistent levels. | Phase 2 GSBR-1290-004 trial (2024) showed up to 14.4% body weight reduction at 36 weeks with the highest dose. Results showed a favorable GI tolerability profile compared to injectable GLP-1 agonists, with lower rates of nausea and vomiting. The oral small-molecule design eliminates the need for injections, potentially improving patient adherence. Structure Therapeutics reported positive Phase 2b results with dose-dependent weight loss across multiple cohorts. |
Frequently Asked Questions: Exenatide vs Eloralintide
What is the difference between Exenatide and Eloralintide?
Exenatide is a weight loss peptide that the first glp-1 receptor agonist approved for diabetes. derived from gila monster saliva. available in twice-daily and weekly formulations. Eloralintide is a weight loss peptide that a next-generation oral glp-1 receptor agonist developed by structure therapeutics (now ventyx biosciences). shows comparable weight loss to injectable glp-1s with potentially fewer gastrointestinal side effects and a longer half-life, allowing flexible dosing. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Exenatide or Eloralintide?
Neither is universally "better" - the choice depends on your specific goals. Exenatide is typically used for weight loss purposes, while Eloralintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Exenatide and Eloralintide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Exenatide and Eloralintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.